On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2504-2522

  Naik, Subhashchandra ^a   Zhang, Na ^b   Gao, Phillip ^b   Fisher, Mark T ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Groel chaperonin; Missense mutations; Pharmacological chaperones; Protein misfolding; Surface plasmon resonance

Indexed keywords

2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); ALPHA 1 ANTITRYPSIN; ALPHA GALACTOSIDASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AQUAPORIN 2; BETA 2 MICROGLOBULIN; BETA GLUCOSIDASE; CHAPERONE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUNTINGTIN; MYOCILIN; PHENYLALANINE 4 MONOOXYGENASE; POLYCYSTIN 2; PREALBUMIN; PROTEIN P53; SUPEROXIDE DISMUTASE; TAFAMIDIS; TAU PROTEIN;

COMPUTER MODEL; CYSTIC FIBROSIS; DISEASES; FLUOROSCOPY; GEL PERMEATION CHROMATOGRAPHY; GENE THERAPY; HUMAN; LIBRARY SCIENCE; MISSENSE MUTATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FOLDING DISEASE; PROTEIN HOMEOSTASIS; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SURFACE PLASMON RESONANCE; ULTRACENTRIFUGATION; UNFOLDED PROTEIN RESPONSE;

CHAPERONIN 60; COMPUTER SIMULATION; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG EVALUATION, PRECLINICAL; GENETIC THERAPY; HIGH-THROUGHPUT SCREENING ASSAYS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; SURFACE PLASMON RESONANCE;

EID: 84874885337     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220006     Document Type: Review

References (111)

1. Dill, K. A.; Chan, H. S. From Levinthal to pathways to funnels. Nat. Struct. Biol., 1997, 4 (1), 10-19.
2. Frauenfelder, H.; Sligar, S. G.; Wolynes, P. G. The energy landscapes and motions of proteins. Science, 1991, 254 (5038), 1598-1603.
3. Onuchic, J. N.; Luthey-Schulten, Z.; Wolynes, P. G. Theory of protein folding: the energy landscape perspective. Annu. Rev. Phys. Chem., 1997, 48, 545-600.
4. Ghosh, K.; Dill, K. Cellular proteomes have broad distributions of protein stability. Biophys. J., 2010, 99 (12), 3996-4002.
5. Morello, J. P.; Petaja-Repo, U. E.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci., 2000, 21 (12), 466-469.
6. Mu, T. W.; Ong, D. S.; Wang, Y. J.; Balch, W. E.; Yates, J. R., 3rd; Segatori, L.; Kelly, J. W. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell, 2008, 134 (5), 769-781.
7. Ringe, D.; Petsko, G. A. What are pharmacological chaperones and why are they interesting? J Biol, 2009, 8 (9), 80.
8. Rajan, R. S.; Tsumoto, K.; Tokunaga, M.; Tokunaga, H.; Kita, Y.; Arakawa, T. Chemical and pharmacological chaperones: appli cation for recombinant protein production and protein folding diseases. Curr. Med. Chem., 2011, 18 (1), 1-15.
9. Henriques, B. J.; Fisher, M. T.; Bross, P.; Gomes, C. M. A polymorphic position in electron transfer flavoprotein modulates kinetic stability as evidenced by thermal stress. FEBS Lett., 2011, 585 (3), 505-510.
10. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388 (6645), 839-840.
11. Citron, M.; Oltersdorf, T.; Haass, C.; McConlogue, L.; Hung, A. Y.; Seubert, P.; Vigo-Pelfrey, C.; Lieberburg, I.; Selkoe, D. J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature, 1992, 360 (6405), 672-674.
12. Kosik, K. S.; Joachim, C. L.; Selkoe, D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A., 1986, 83 (11), 4044-4048.
13. Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J. P.; Deng, H.-X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S. M.; Berger, R.; Tanzi, R. E.; Halperin, J. J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.-Y.; Bird, T.; Deng, G.; Mulder, D. W.; Smyth, C.; Laing, N. G.; Soriano, E.; Pericak-Vance, M. A.; Haines, J.; Rouleau, G. A.; Gusella, J. S.; Horvitz, H. R.; Brown, R. H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362 (6415), 59-62.
14. Scherzinger, E.; Lurz, R.; Turmaine, M.; Mangiarini, L.; Hollenbach, B.; Hasenbank, R.; Bates, G. P.; Davies, S. W.; Lehrach, H.; Wanker, E. E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 1997, 90 (3), 549-558.
15. Cheng, S. H.; Gregory, R. J.; Marshall, J.; Paul, S.; Souza, D. W.; White, G. A.; O'Riordan, C. R.; Smith, A. E. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell, 1990, 63 (4), 827-834.
16. Ron, I.; Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet., 2005, 14 (16), 2387-2398.
17. Eng, C. M.; Desnick, R. J. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum. Mutat., 1994, 3 (2), 103-111.
18. Mulders, S. M.; Bichet, D. G.; Rijss, J. P.; Kamsteeg, E. J.; Arthus, M. F.; Lonergan, M.; Fujiwara, M.; Morgan, K.; Leijendekker, R.; van der Sluijs, P.; van Os, C. H.; Deen, P. M. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J. Clin. Invest., 1998, 102 (1), 57-66.
19. Gejyo, F.; Homma, N.; Suzuki, Y.; Arakawa, M. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N. Engl. J. Med., 1986, 314 (9), 585-586.
20. Saraiva, M. J.; Birken, S.; Costa, P. P.; Goodman, D. S. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest., 1984, 74 (1), 104-119.
21. Waters, P. J.; Parniak, M. A.; Akerman, B. R.; Scriver, C. R. Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. Mol. Genet. Metab., 2000, 69 (2), 101-110.
22. Cai, Y.; Wang, J.; Ren, C.; Ittmann, M. Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation analysis. PLoS One, 2012, 7 (2), e32708.
23. Stehr, H.; Jang, S. H.; Duarte, J. M.; Wierling, C.; Lehrach, H.; Lappe, M.; Lange, B. M. The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Mol Cancer, 2011, 10, 54.
24. Tomasson, M. H.; Xiang, Z.; Walgren, R.; Zhao, Y.; Kasai, Y.; Miner, T.; Ries, R. E.; Lubman, O.; Fremont, D. H.; McLellan, M. D.; Payton, J. E.; Westervelt, P.; DiPersio, J. F.; Link, D. C.; Walter, M. J.; Graubert, T. A.; Watson, M.; Baty, J.; Heath, S.; Shannon, W. D.; Nagarajan, R.; Bloomfield, C. D.; Mardis, E. R.; Wilson, R. K.; Ley, T. J. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood, 2008, 111 (9), 4797-4808.
25. Minde, D. P.; Anvarian, Z.; Rudiger, S. G.; Maurice, M. M. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer, 2011, 10, 101.
26. Koutnikova, H.; Campuzano, V.; Koenig, M. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum. Mol. Genet., 1998, 7 (9), 1485-1489.
27. Pey, A. L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest., 2008, 118 (8), 2858-2867.
28. Sands, M. S.; Davidson, B. L. Gene therapy for lysosomal storage diseases. Mol Ther, 2006, 13 (5), 839-849.
29. Alt, M.; Caselmann, W. H. Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. J. Hepatol., 1995, 23 (6), 746-758.
30. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Adapting proteostasis for disease intervention. Science, 2008, 319 (5865), 916-919.
31. Bernado, P.; Blackledge, M. Structural biology: Proteins in dynamic equilibrium. Nature, 2010, 468 (7327), 1046-1048.
32. Flotte, T. R.; Zeitlin, P. L.; Reynolds, T. C.; Heald, A. E.; Pedersen, P.; Beck, S.; Conrad, C. K.; Brass-Ernst, L.; Humphries, M.; Sullivan, K.; Wetzel, R.; Taylor, G.; Carter, B. J.; Guggino, W. B. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther., 2003, 14 (11), 1079-1088.
33. Moss, R. B.; Milla, C.; Colombo, J.; Accurso, F.; Zeitlin, P. L.; Clancy, J. P.; Spencer, L. T.; Pilewski, J.; Waltz, D. A.; Dorkin, H. L.; Ferkol, T.; Pian, M.; Ramsey, B.; Carter, B. J.; Martin, D. B.; Heald, A. E. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum. Gene Ther., 2007, 18 (8), 726-732.
34. Hannon, G. J. RNA interference. Nature, 2002, 418 (6894), 244-251.
35. Li, C.; Xiao, P.; Gray, S. J.; Weinberg, M. S.; Samulski, R. J. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc. Natl. Acad. Sci. U. S. A., 2011, 108 (34), 14258-14263.
36. Thomas, P. J.; Ko, Y. H.; Pedersen, P. L. Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett., 1992, 312 (1), 7-9.
37. Pind, S.; Riordan, J. R.; Williams, D. B. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem., 1994, 269 (17), 12784-12788.
38. Yang, Y.; Janich, S.; Cohn, J. A.; Wilson, J. M. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. U. S. A., 1993, 90 (20), 9480-9484.
39. Meacham, G. C.; Lu, Z.; King, S.; Sorscher, E.; Tousson, A.; Cyr, D. M. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J., 1999, 18 (6), 1492-1505.
40. Ward, C. L.; Kopito, R. R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J. Biol. Chem., 1994, 269 (41), 25710-25718.
41. Denning, G. M.; Anderson, M. P.; Amara, J. F.; Marshall, J.; Smith, A. E.; Welsh, M. J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature, 1992, 358 (6389), 761-764.
42. Hulleman J.D., Kaushal S., Balch W.E., Kelly J.W., Compromised mutant EFEMP1 secretion associated with macular dystrophy remedied by proteostasis network alteration. Mol Biol Cell.2011 22(24),4765-4775.
43. Brown, C. R.; Hong-Brown, L. Q.; Biwersi, J.; Verkman, A. S.; Welch, W. J. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones, 1996, 1 (2), 117-125.
44. Yancey, P. H.; Clark, M. E.; Hand, S. C.; Bowlus, R. D.; Somero, G. N. Living with water stress: evolution of osmolyte systems. Science, 1982, 217 (4566), 1214-1222.
45. Bolen, D. W.; Rose, G. D. Structure and energetics of the hydrogen-bonded backbone in protein folding. Annu. Rev. Biochem., 2008, 77, 339-362.
46. Jia, L. Y.; Gong, B.; Pang, C. P.; Huang, Y.; Lam, D. S.; Wang, N.; Yam, G. H. Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. Invest. Ophthalmol. Vis. Sci., 2009, 50 (8), 3743-3749.
47. Burrows, J. A.; Willis, L. K.; Perlmutter, D. H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. U. S. A., 2000, 97 (4), 1796-1801.
48. Tamarappoo, B. K.; Yang, B.; Verkman, A. S. Misfolding of mutant aquaporin-2 water channels in nephrogenic diabetes insipidus. J. Biol. Chem., 1999, 274 (49), 34825-34831.
49. Song, J. L.; Chuang, D. T. Natural osmolyte trimethylamine N-oxide corrects assembly defects of mutant branched-chain alpha-ketoacid decarboxylase in maple syrup urine disease. J. Biol. Chem., 2001, 276 (43), 40241-40246.
50. Vassilev, P. M.; Guo, L.; Chen, X. Z.; Segal, Y.; Peng, J. B.; Basora, N.; Babakhanlou, H.; Cruger, G.; Kanazirska, M.; Ye, C.; Brown, E. M.; Hediger, M. A.; Zhou, J. Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem. Biophys. Res. Commun., 2001, 282 (1), 341-350.
51. Ohnishi, T.; Ohnishi, K.; Wang, X.; Takahashi, A.; Okaichi, K. Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone. Radiat. Res., 1999, 151 (4), 498-500.
52. Leandro, P.; Lechner, M. C.; Tavares de Almeida, I.; Konecki, D. Glycerol increases the yield and activity of human phenylalanine hydroxylase mutant enzymes produced in a prokaryotic expression system. Mol. Genet. Metab., 2001, 73 (2), 173-178.
53. Deen, P. M.; Croes, H.; van Aubel, R. A.; Ginsel, L. A.; van Os, C. H. Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J. Clin. Invest., 1995, 95 (5), 2291-2296.
54. Marr, N.; Bichet, D. G.; Lonergan, M.; Arthus, M. F.; Jeck, N.; Seyberth, H. W.; Rosenthal, W.; van Os, C. H.; Oksche, A.; Deen, P. M. Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/ lysosomes explains dominant nephrogenic diabetes insipidus. Hum. Mol. Genet., 2002, 11 (7), 779-789.
55. Novak, J. E.; Turner, R. S.; Agranoff, B. W.; Fisher, S. K. Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. J. Neurochem., 1999, 72 (4), 1431-1440.
56. Gidalevitz, T.; Kikis, E. A.; Morimoto, R. I. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr. Opin. Struct. Biol., 2010, 20 (1), 23-32.
57. Powers, E. T.; Morimoto, R. I.; Dillin, A.; Kelly, J. W.; Balch, W. E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem., 2009, 78, 959-991.
58. Morimoto, R. I. The heat shock response: systems biology of proteotoxic stress in aging and disease. Cold Spring Harb. Symp. Quant. Biol., 2011, 76, 91-99.
59. Morello, J. P.; Salahpour, A.; Laperriere, A.; Bernier, V.; Arthus, M. F.; Lonergan, M.; Petaja-Repo, U.; Angers, S.; Morin, D.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest., 2000, 105 (7), 887-895.
60. Janovick, J. A.; Goulet, M.; Bush, E.; Greer, J.; Wettlaufer, D. G.; Conn, P. M. Structure-activity relations of successful pharma cologic chaperones for rescue of naturally occurring and manu factured mutants of the gonadotropin-releasing hormone receptor. J. Pharmacol. Exp. Ther., 2003, 305 (2), 608-614.
61. Davies, J. W.; Glick, M.; Jenkins, J. L. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr. Opin. Chem. Biol., 2006, 10 (4), 343-351.
62. Nowak, R. J.; Cuny, G. D.; Choi, S.; Lansbury, P. T.; Ray, S. S. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyo trophic lateral sclerosis using computational methods. J. Med. Chem., 2010, 53 (7), 2709-2718.
63. Bulawa, C. E.; Connelly, S.; Devit, M.; Wang, L.; Weigel, C.; Fleming, J. A.; Packman, J.; Powers, E. T.; Wiseman, R. L.; Foss, T. R.; Wilson, I. A.; Kelly, J. W.; Labaudiniere, R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U. S. A., 2012, 109 (24), 9629-9634.
64. Cohen, F. E.; Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature, 2003, 426 (6968), 905-909.
65. Lieberman, R. L.; D'Aquino J.A.; Ringe, D.; Petsko, G. A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry (Mosc).2009, 48 (22), 4816-4827.
66. Lieberman, R. L.; Wustman, B. A.; Huertas, P.; Powe, A. C., Jr.; Pine, C. W.; Khanna, R.; Schlossmacher, M. G.; Ringe, D.; Petsko, G. A. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol, 2007, 3 (2), 101-107.
67. Ray, S. S.; Nowak, R. J.; Brown, R. H., Jr.; Lansbury, P. T., Jr. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. U. S. A., 2005, 102 (10), 3639-3644.
68. Pedemonte, N.; Lukacs, G. L.; Du, K.; Caci, E.; Zegarra-Moran, O.; Galietta, L. J.; Verkman, A. S. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest., 2005, 115 (9), 2564-2571.
69. Van Goor, F.; Straley, K. S.; Cao, D.; Gonzalez, J.; Hadida, S.; Hazlewood, A.; Joubran, J.; Knapp, T.; Makings, L. R.; Miller, M.; Neuberger, T.; Olson, E.; Panchenko, V.; Rader, J.; Singh, A.; Stack, J. H.; Tung, R.; Grootenhuis, P. D.; Negulescu, P. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol, 2006, 290 (6), L1117-1130.
70. Carlile, G. W.; Robert, R.; Zhang, D.; Teske, K. A.; Luo, Y.; Hanrahan, J. W.; Thomas, D. Y. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem, 2007, 8 (9), 1012-1020.
71. Lee L.L., Ha H., Chang Y.T., DeLisa M.P., Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellu-lar protein folding and solubility. Protein Sci. 2009 18(2), 277-286.
72. Ignatova, Z.; Gierasch, L. M. Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (36), 13357-13361.
73. Pantoliano, M. W.; Petrella, E. C.; Kwasnoski, J. D.; Lobanov, V. S.; Myslik, J.; Graf, E.; Carver, T.; Asel, E.; Springer, B. A.; Lane, P.; Salemme, F. R. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen, 2001, 6 (6), 429-440.
74. Cummings, M. D.; Farnum, M. A.; Nelen, M. I. Universal screening methods and applications of ThermoFluor. J Biomol Screen, 2006, 11 (7), 854-863.
75. Lavinder, J. J.; Hari, S. B.; Sullivan, B. J.; Magliery, T. J. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J. Am. Chem. Soc., 2009, 131 (11), 3794-3795.
76. Janovick, J. A.; Park, B. S.; Conn, P. M. Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. PLoS ONE, 2011, 6 (7), e22784.
77. Mayer, M. P.; Schroder, H.; Rudiger, S.; Paal, K.; Laufen, T.; Bukau, B. Multistep mechanism of substrate binding determines chaperone activity of Hsp70. Nat. Struct. Biol., 2000, 7 (7), 586-593.
78. Kampinga, H. H.; Craig, E. A. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol., 2010, 11 (8), 579-592.
79. Krukenberg, K. A.; Street, T. O.; Lavery, L. A.; Agard, D. A. Conformational dynamics of the molecular chaperone Hsp90. Q. Rev. Biophys., 2011, 44 (2), 229-255.
80. Sittler, A.; Lurz, R.; Lueder, G.; Priller, J.; Lehrach, H.; Hayer-Hartl, M. K.; Hartl, F. U.; Wanker, E. E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 2001, 10 (12), 1307-1315.
81. Auluck, P. K.; Chan, H. Y.; Trojanowski, J. Q.; Lee, V. M.; Bonini, N. M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science, 2002, 295 (5556), 865-868.
82. Dou, F.; Netzer, W. J.; Tanemura, K.; Li, F.; Hartl, F. U.; Takashima, A.; Gouras, G. K.; Greengard, P.; Xu, H. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. U. S. A., 2003, 100 (2), 721-726.
83. Jinwal, U. K.; Miyata, Y.; Koren, J., 3rd; Jones, J. R.; Trotter, J. H.; Chang, L.; O'Leary, J.; Morgan, D.; Lee, D. C.; Shults, C. L.; Rousaki, A.; Weeber, E. J.; Zuiderweg, E. R.; Gestwicki, J. E.; Dickey, C. A. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci., 2009, 29 (39), 12079-12088.
84. Barnett, M. E.; Nagy, M.; Kedzierska, S.; Zolkiewski, M. The amino-terminal domain of ClpB supports binding to strongly aggregated proteins. J. Biol. Chem., 2005, 280 (41), 34940-34945.
85. Weibezahn, J.; Tessarz, P.; Schlieker, C.; Zahn, R.; Maglica, Z.; Lee, S.; Zentgraf, H.; Weber-Ban, E. U.; Dougan, D. A.; Tsai, F. T.; Mogk, A.; Bukau, B. Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB. Cell, 2004, 119 (5), 653-665.
86. Schlieker, C.; Tews, I.; Bukau, B.; Mogk, A. Solubilization of aggregated proteins by ClpB/DnaK relies on the continuous extraction of unfolded polypeptides. FEBS Lett., 2004, 578 (3), 351-356.
87. Lum, R.; Tkach, J. M.; Vierling, E.; Glover, J. R. Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104. J. Biol. Chem., 2004, 279 (28), 29139-29146.
88. Schlieker, C.; Weibezahn, J.; Patzelt, H.; Tessarz, P.; Strub, C.; Zeth, K.; Erbse, A.; Schneider-Mergener, J.; Chin, J. W.; Schultz, P. G.; Bukau, B.; Mogk, A. Substrate recognition by the AAA+ chaperone ClpB. Nat. Struct. Mol. Biol., 2004, 11 (7), 607-615.
89. Chernoff, Y. O.; Lindquist, S. L.; Ono, B.; Inge-Vechtomov, S. G.; Liebman, S. W. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science, 1995, 268 (5212), 880-884.
90. Doyle, S. M.; Shorter, J.; Zolkiewski, M.; Hoskins, J. R.; Lindquist, S.; Wickner, S. Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat. Struct. Mol. Biol., 2007, 14 (2), 114-122.
91. Estorninho, M.; Smith, H.; Thole, J.; Harders-Westerveen, J.; Kierzek, A.; Butler, R. E.; Neyrolles, O.; Stewart, G. R. ClgR regulation of chaperone and protease systems is essential for Mycobacterium tuberculosis parasitism of the macrophage. Microbiology, 2010, 156 (Pt 11), 3445-3455.
92. de Koning-Ward, T. F.; Gilson, P. R.; Boddey, J. A.; Rug, M.; Smith, B. J.; Papenfuss, A. T.; Sanders, P. R.; Lundie, R. J.; Maier, A. G.; Cowman, A. F.; Crabb, B. S. A newly discovered protein export machine in malaria parasites. Nature, 2009, 459 (7249), 945-949.
93. Krobitsch, S.; Clos, J. A novel role for 100 kD heat shock proteins in the parasite Leishmania donovani. Cell Stress Chaperones, 1999, 4 (3), 191-198.
94. Kim, K. I.; Cheong, G. W.; Park, S. C.; Ha, J. S.; Woo, K. M.; Choi, S. J.; Chung, C. H. Heptameric ring structure of the heat-shock protein ClpB, a protein-activated ATPase in Escherichia coli. J. Mol. Biol., 2000, 303 (5), 655-666.
95. Parsell, D. A.; Kowal, A. S.; Lindquist, S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-induced structural changes. J. Biol. Chem., 1994, 269 (6), 4480-4487.
96. Schlee, S.; Groemping, Y.; Herde, P.; Seidel, R.; Reinstein, J. The chaperone function of ClpB from Thermus thermophilus depends on allosteric interactions of its two ATP-binding sites. J. Mol. Biol., 2001, 306 (4), 889-899.
97. Watanabe, Y. H.; Motohashi, K.; Yoshida, M. Roles of the two ATP binding sites of ClpB from Thermus thermophilus. J. Biol. Chem., 2002, 277 (8), 5804-5809.
98. Zolkiewski, M. ClpB cooperates with DnaK, DnaJ, and GrpE in suppressing protein aggregation. A novel multi-chaperone system from Escherichia coli. J. Biol. Chem., 1999, 274 (40), 28083-28086.
99. Van Dyk, T. K.; Gatenby, A. A.; LaRossa, R. A. Demonstration by genetic suppression of interaction of GroE products with many proteins. Nature, 1989, 342 (6248), 451-453.
100. Tokuriki, N.; Tawfik, D. S. Chaperonin overexpression promotes genetic variation and enzyme evolution. Nature, 2009, 459 (7247), 668-673.
101. Chapman, E.; Farr, G. W.; Usaite, R.; Furtak, K.; Fenton, W. A.; Chaudhuri, T. K.; Hondorp, E. R.; Matthews, R. G.; Wolf, S. G.; Yates, J. R.; Pypaert, M.; Horwich, A. L. Global aggregation of newly translated proteins in an Escherichia coli strain deficient of the chaperonin GroEL. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (43), 15800-15805.
102. Viitanen, P. V.; Donaldson, G. K.; Lorimer, G. H.; Lubben, T. H.; Gatenby, A. A. Complex interactions between the chaperonin 60 molecular chaperone and dihydrofolate reductase. Biochemistry (Mosc).1991, 30 (40), 9716-9723.
103. Smith, K. E.; Voziyan, P. A.; Fisher, M. T. Partitioning of rhodanese onto GroEL. Chaperonin binds a reversibly oxidized form derived from the native protein. J. Biol. Chem., 1998, 273 (44), 28677-28681.
104. Naik, S.; Haque, I.; Degner, N.; Kornilayev, B.; Bomhoff, G.; Hodges, J.; Khorassani, A. A.; Katayama, H.; Morris, J.; Kelly, J.; Seed, J.; Fisher, M. T. Identifying protein stabilizing ligands using GroEL. Biopolymers, 2010, 93 (3), 237-251.
105. Katayama, H.; McGill, M.; Kearns, A.; Brzozowski, M.; Degner, N.; Harnett, B.; Kornilayev, B.; Matkovic-Calogovic, D.; Holyoak, T.; Calvet, J. P.; Gogol, E. P.; Seed, J.; Fisher, M. T. Strategies for folding of affinity tagged proteins using GroEL and osmolytes. J Struct. Funct Genomics, 2009, 10 (1), 57-66.
106. Voziyan, P. A.; Jadhav, L.; Fisher, M. T. Refolding a glutamine synthetase truncation mutant in vitro: identifying superior condi tions using a combination of chaperonins and osmolytes. J. Pharm. Sci., 2000, 89 (8), 1036-1045.
107. Lin, Z.; Eisenstein, E. Nucleotide binding-promoted confor mational changes release a nonnative polypeptide from the Escherichia coli chaperonin GroEL. Proc. Natl. Acad. Sci. U. S. A., 1996, 93 (5), 1977-1981.
108. Murai, N.; Taguchi, H.; Yoshida, M. Kinetic analysis of interactions between GroEL and reduced alpha-lactalbumin. Effect of GroES and nucleotides. J. Biol. Chem., 1995, 270 (34), 19957-19963.
109. Fenton, W. A.; Horwich, A. L. GroEL-mediated protein folding. Protein Sci., 1997, 6 (4), 743-760.
110. Martin, J.; Horwich, A. L.; Hartl, F. U. Prevention of protein denaturation under heat stress by the chaperonin Hsp60. Science, 1992, 258 (5084), 995-998.
111. Voziyan, P. A. Fisher, M. T. Chaperonin-assisted folding of glutamine synthetase under nonpermissive conditions: off-pathway aggregation propensity does not determine the co-chaperonin requirement. Protein Sci., 2000, 9 (12), 2405-2412.